期刊文献+

120例乳腺癌患者根治术后的临床病理特征 被引量:5

下载PDF
导出
摘要 目的利用酶联免疫吸附法检测乳腺癌患者手术前后血清中表皮生长因子受体2胞外域的浓度水平,以探讨乳腺癌患者手术前后血清表皮生长因子受体2胞外域的水平变化及其临床意义。方法收集笔者所在医院外科手术经病理证实的120名乳腺癌患者手术前后的血清,用ELISA法检测血清中表皮生长因子受体2胞外域的浓度水平,并与患者的绝经状态、肿瘤大小、临床分期等临床因素进行比较。结果 120例乳腺癌患者手术前血清表皮生长因子受体2胞外域浓度明显高于正常人和良性乳腺病患者,差异具有统计学意义,且与肿瘤大小、临床分期显著相关。结论乳腺癌患者血清表皮生长因子受体2胞外域水平明显高于正常人和良性乳腺病患者,血清表皮生长因子受体2胞外域水平可能可作为临床上预测乳腺癌患者手术疗效的指标。
作者 杨光建
出处 《中国医学创新》 CAS 2010年第4期190-191,共2页 Medical Innovation of China
  • 相关文献

参考文献3

  • 1刘彩云,寿成超.乳腺癌患者血清HER-2/neu胞外域的临床意义[J].国际检验医学杂志,2006,27(3):237-239. 被引量:7
  • 2Mazouni C;Hall A;Broqlio K.Kinetics of serum HER-2/neu changes in patients with HER positive primary breast cancer after initiation of primary chemotherapy[J],2007(03).
  • 3Slamon DJ;Clark GM;Wong SG.Human breast cancer:correlation of relapse and survival with amplification of the HER-2/neu oncogene,1987(4785).

二级参考文献17

  • 1Carney WP,Neumann R,Lipton A,et al.Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer.Clin Chem,2003,49(10):1579-1598.
  • 2Carney WP,Neumann R,Lipton A,et al.Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer.Clin Breast Cancer,2004,5(2):105-116.
  • 3Muller V,Witzel I,Luck HJ,et al.Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.Breast Cancer Res Treat,2004,86(1):9-18.
  • 4Luftner D,Henschke P,Kafka A,et al.Discordant results obtained for different methods of HER-2/neu testing in breast cancer--a question of standardization,automation and timing.Int J Biol Markers,2004,19(1):1-13.
  • 5Muller V,Thomssen C,Karakas C,et al.Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay.Int J Biol Markers,2003,18(1):13-20.
  • 6Esteva FJ,Valero V,Booser D,et al.Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.J Clin Oncol,2002,20(7):1800-1808.
  • 7Saghatchian M,Guepratte S,Hacene K,et al.Serum HER-2 extracellular domain:relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients.Int J Biol Markers,2004,19(1):14-22.
  • 8Pichon MF,Hacene K,Guepratte S,et al.Serum HER-2 extracellular domain (ECD) before the first metastasis in 128 breast cancer patients.Clin Lab,2004,50(3-4):163-170.
  • 9Schippinger W,Regitnig P,Bauernhofer T,et al.The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.Oncol Rep,2004,11(6):1331-1336.
  • 10Kostler WJ,Schwab B,Singer CF,et al.Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer.Clin Cancer Res,2004,10(5):1618-1624.

共引文献6

同被引文献41

引证文献5

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部